This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra in patients with moderate to severe rheumatoid arthritis who have completed the 97-week WA22762 core study. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01734993?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
